<DOC>
	<DOC>NCT01354431</DOC>
	<brief_summary>The purpose of this study is to measure how active BMS-936558 (nivolumab) is against Renal Cell Carcinoma (RCC) as measured by the disease not progressing and whether a dose response relationship exists.</brief_summary>
	<brief_title>BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Histologic confirmation of Renal cell carcinoma (RCC) with a clear cell component Previous treatment with at least one antiangiogenic agent Progressed within 6 months of study enrollment Subjects should not have had more than 3 prior treatments for locally advanced or metastatic disease Must have available tumor tissue for submission Subjects must also meet various laboratory parameters for inclusion Subjects with any active autoimmune disease or a history of known autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Advanced/Metastatic</keyword>
	<keyword>clear cell component</keyword>
</DOC>